MITIGO

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF MITIGO ® WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF MITIGO ® Risks with Neuraxial Administration Single-dose neuraxial administration may result in acute or delayed respiratory depression up to 24 hours. Because of the risk of severe adverse reactions when MITIGO ® is administered by the epidural or intrathecal route of administration, patients must be observed in a fully equipped and staffed environment for at least 24 hours after the initial dose [see Warnings and Precautions ( 5.1 ) ] . Addiction, Abuse, and Misuse Because the use of MITIGO ® exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions ( 5.2 )] . Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of MITIGO ® , especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of MITIGO ® are essential [see Warnings and Precautions ( 5.3 ) ] . Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of MITIGO ® and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate [see Warnings and Precautions ( 5.4 ), Drug Interactions ( 7 )] . Neonatal Opioid Withdrawal Syndrome (NOWS) Advise pregnant women using opioids for an extended period of time of the risk Neonatal Opioid Withdrawal Syndrome, which may be life threatening if not recognized and treated. Ensure that management by n